Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
Y CombinatorWinter 2022ActiveHealthcareTherapeuticsBiotechTherapeuticsDrug discoveryOncology
What they do
Problem
Cancer treatments often fail due to drug resistance driven by metabolic and inflammatory processes in the tumor microenvironment.
Solution
Alixia develops compounds that disrupt metabolic and inflammatory triggers across cancer and quasi-cancerous cells within the tumor microenvironment to enable more durable cancer therapies.
Who it's for
Oncology drug developers and cancer treatment providers seeking therapies that overcome tumor drug resistance.
Founders
Olof Mollstedt
Founder
Helen Chen
Founder
Cancer & aging researcher | entrepreneur| mentor |
Company timeline
- Founded2022
- YC batchWinter 2022
- StatusActive
- Team size2 people
- LocationSan Francisco, CA, USA
Similar startups
Earli
Programmable genetic constructs expressed only in cancer cells for ta…
Kopra Bio
Genetically engineered viruses that teach your immune system to kill…
Shasqi
Targeting Cancer with Click Chemistry
Numen
Engineering a future without cancer deaths.
Stipple Bio
An "epitomics" platform to define and drug cancer-specific epitopes o…
ResistanceBio
We solve drug resistance for cancer